Since then, the company has received FDA approval for a number of genetic tests that quantify health risks for conditions like Parkinson’s or breast cancer, to name a few. But as for regulatory strategy, the company initially plans to go a route once used by Ancestry – order tests from a clinical network, rather than creating their own. That does allow the company to sidestep FDA approval of its algorithms at first (this process is regulated by the Centers for Medicare and Medicaid). In the meantime, the company plans to launch sometime around January 2022 and has plans to grow the team from three to six or seven members. “It’s an imminent inevitability that every person has the human genome sequence,” said Sadeghi.